ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings
The CARISEL study showed most people living with HIV who started treatment felt positive about the long-acting regimen
